Cell cycle arrest in endometrial carcinoma cells exposed to gonadotropin-releasing hormone analog

J W Kim1, Y S Lee, B K Kim

  • 1Kangnam St. Mary's Hospital, Catholic Research Institutes of Medical Science, Catholic University Medical College, 505 Banpo-dong, Seocho-ku, Seoul, 137-040, Korea.

Gynecologic Oncology
|June 15, 1999
PubMed

Insights

Gonadotropin-releasing hormone (GnRH) analogs, like D-Trp6-LHRH, can inhibit endometrial cancer cell growth. This study found GnRH treatment causes cell cycle arrest at the G1-S transition, suggesting a novel therapeutic mechanism.

Area of Science:

  • Oncology
  • Endocrinology
  • Cell Biology

Background:

  • Gonadotropin-releasing hormone (GnRH) exhibits inhibitory effects on various hormone-dependent human tumors.
  • Endometrial cancer is a significant gynecological malignancy where hormone dependency plays a role in growth.

Purpose of the Study:

  • To investigate the cell cycle kinetic response of a human endometrial cancer cell line expressing GnRH receptors upon treatment with a GnRH analog.
  • To elucidate the potential mechanisms underlying GnRH's inhibitory effect on endometrial carcinoma cell proliferation.

Main Methods:

  • Utilized a human endometrial cancer cell line with confirmed GnRH receptor expression.
  • Administered the GnRH analog D-Trp6-LHRH at a concentration of 10 microM for 36 hours.
  • Performed flow cytometric analysis to assess cell cycle distribution.
  • Conducted Western blot analysis to evaluate protein expression levels, specifically p16.

Main Results:

  • Flow cytometry revealed a significant cell cycle arrest at the G1-S transition in treated endometrial cancer cells.
  • Western blot analysis indicated an increased level of p16 protein after 24 hours of D-Trp6-LHRH treatment.
  • The observed cell cycle arrest and p16 upregulation suggest a direct impact of GnRH on cell cycle regulation.

Conclusions:

  • GnRH analog treatment effectively induces cell cycle arrest in human endometrial cancer cells.
  • The p16 protein upregulation is a potential mechanism contributing to GnRH-mediated growth inhibition.
  • These findings support the potential of GnRH-based therapies for managing endometrial carcinoma.

Related Concept Videos

Ovarian Cycle01:27

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Cell Cycle Control System01:28

The Cell Cycle Control System

The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
Molecular Factors Affecting Cell Division01:27

Molecular Factors Affecting Cell Division

Several external and internal factors influence the initiation and inhibition of cell division. For instance, the death of nearby cells or the release of human growth hormone (hGH) promotes cell division. In contrast, lack of hGH or crowding of cells can inhibit cell division.
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...